the study. Only one of the 88 anatomic regions that was completely uninvolved at the beginning of the study became involved during isotretinoin therapy. However, 16 of the 21 patients (76%) had major flare ups develop in 38 of 143 (27%) previously involved anatomic regions while administered isotretinoin therapy. Isotretinoin at steady state doses of 1 to 2 mg/kg per day decreased the incidence of heterotopic ossification at uninvolved anatomic regions compared with an external control group, as long as the medication was started before the appearance of any orthotopic or heterotopic ossification in that anatomic region. The data did not allow the determination of whether isotretinoin was effective or detrimental in preventing disease flareups in regions that had even minimal orthotopic or heterotopic ossification at the time the therapy began. Extreme caution should be exercised when using this medication in patients who have fibrodysplasia ossificans progressiva.
Retinoids are a plausible family of therapeutic agents for fibrodysplasia ossificans progressiva due to their ability to inhibit differentiation of mesenchymal tissue into cartilage and bone. A prospective study was conducted to assess the efficacy of isotretinoin (13-cis-retinoic acid) in the prevention of heterotopic ossification in patients who had fibrodysplasia ossificans progressiva. Eleven anatomic regions were assessed in each of 21 patients by clinical examiadiographs. and bonẽ if there was clinical, radiographic, or radionuelide evidence of orthotopic or heterotopic ossification anywhere in the region. There were 143 involved anatomic regions and 88 uninvolved anatomic regions at the beginning of The phenotype and natural history of tibrodysplasia ossiticans progressiva have been well detined.4.7.9.10. 24-26.36.37.40-43 Retinoids are a plausible family of therapeutic agents for fibrodysplasia ossificans progressiva, principally because of their ability to inhibit differentiation of mesenchymal tissue into cartilage Kaplan On the basis of these preliminary findings, the authors conducted a prospective study to assess the safety and efficacy of 13-cis-retinoic acid in the prevention of new heterotopic lesions in patients who had fibrodysplasia ossificans progressiva. .t toes of soft the study, and at the conclusion of the study. Patients were contacted in person, by telephone, or by mail as many as 6 years after termination of the study, and asked to complete a brief questionnaire about the subsequent course of fibrodysplasia ossificans progressiva flareups. For the purposes of this study, the investigators defined an anatomic region as that area typically represented by any of the following domains on clinical, radiographic, or radionuclide bone scan: the cervical spine, thoracolumbar spine, right shoulder, left shoulder, right elbow, left elbow, right hip, left hip, right knee, left knee, and jaw. The authors considered an anatomic region to be involved with fibrodysplasia ossificans progressiva if there was any clinical, radiographic, or radionuclide evidence of orthotopic or heterotopic ossification anywhere in that region. Conversely, a joint was considered to be uninvolved only if all three modes of evaluation (clinical examination, radiographic evaluation, and radionuclide bone scan) showed no evidence of orthotopic or heterotopic ossification in that region. A complete blood count, plasma transaminase levels, and plasma triglyceride levels were obtained on each patient at entry into the study, at 6-month intervals during the study, and at the conclusion of the study.
Patients who entered the study were treated with a single bedtime oral dose of isotretinoin at a concentration of 1 mgikg per day. The dose was raised by I mg/kg per day for 2-week intervals until a final dose of 5 to 8 mg/kg per day was reached. The medication dosage was adjusted downward if side effects of cheilitis, xerosis, hair loss, dry nasal mucosa, or dry mouth developed in the patient.
Data on regional involvement were collated from the studies in each patient and from the external control study on fibrodysplasia ossificans progressiva!.36 A multivariate survival model ; fit to the data using software developed specifically for this purpose.J.II.J9.46.47 Assessment of statistical significance was calculated using the robust variance approach.46 RESULTS Twentv-one patients were enrolled in the o;(udy during the 5-year period between January 1984 and December 1988 (Table I ). Eleven anatomic regions were assessed in 21 patients for a total of 231 anatomic regionS (Table 2) ... One hundred forty--three anatomic regions were involved with orthotopic or heterotopic bone at the beginning of the study. One hundred forty-four anatomic regions were involved with orthotopic or heterotopic bone at the end of the study. There were 88 uninvolved anatomic regions at the beginning of the study, and 87 uninvolved anatomic regions at the conclusion of the study. Only one anatomic region that was completely uninvolved at the beginning of the study became involved during the course of the study because of an episode of blunt trauma to the left knee (Table 2; Patient 11). Heterotopic ossification developed rapidly in the patient at the site of trauma, and this patient was the only one in the study who sustained heterotopic ossification in a region that had been completely uninvolved at the time that isotretinoin therapy was begun. Among the 11 patients who were able to complete 3 or more years of isotretinoin therapy, steady state doses ranged from 0.5 mg/kg per day to 8 mg/kg per day (median, 1.7 mg/kg per day). In the 11 patients who received medication for 3 years or more, there was no significant difference in the rate of new heterotopic ossification between those who received more than 1.7 mg/kg per day of isotretinoin and those who received less than 1.7 mg/kg per day of isotretinoin. Also, there was no significant difference in the rate of new heterotopic ossification between those 14 patients who received intercurrent treatment with nonsteroidal antiinflammatory medications or etidronate and those seven patients who received only isotretinoin. However, the very small sample sizes mean that differences may have existed that could not be detected with the present data.
The relative risk of heterotopic ossification in a previously uninvolved anatomic region for those treated with isotretinoin was 0.117 corresponding to a reduction in risk of 88% (95% confidence interval: 0.008-0.497; 50% reduction to 99% reduction), compared with a relative risJ< of 1.00 for those patients in the external control group (p = 0.0013). t progressiva. The authors have no evidence as to whether isotretinoin changed the risk of heterotopic ossification in anatomic regions that were even minimally involved with orthotopic or heterotopic bone at the time therapy was instituted. Although isotretinoin seemed to have some limited use in the prevention of spontaneous heterotopic ossification in patients who had fibrodysplasia ossificans progressiva, it had no apparent benefit in the prevention of heterotopic ossification after surgery in those patients.12 Furthermore, it is doubtful that isotretinoin had any effect in the prevention of heterotopic ossification after soft tissue trauma. Most of the patients who received isotretinoin already had experienced ossification of the cervical spine, thoracolumbar spine, and upper limbs, and there was no benefit of therapy in those regions. If there was a beneficial regional effect of isotretinoin therapy, it was in the lower limbs (especially at the hips and knees), because those anatomic regions were less likely to be affected with orthotopic or heterotopic ossification at a young age when isotretinoin therapy was instituted. Despite thẽ tentialbenefits of isotretinoin, it was clearly not a panacea for fibrodysplasia ossificans progressiva, because 16 of the 21 patients (76%) had major flareups of previously involved areas develop while administered isotretinoin therapy. Although these flareups were likely attributable to the natural history of the disease, the authors cannot exclude the possibility of a paradoxical stimulation of orthotopic or heterotopic ossification in regions already afflicted with those processes.5,15.16.17.23,34
The temporal and spatial progression of lesions in patients who have fibrodysplasia ossificans progressiva follows patterns similar to those seen during normal skeletal embryogenesis.' ,26,42 The molecular basis of this sequential involvement is unknown but may involve the secretion of diffusible morphogens that establish the tissue specific patterns of gene expression.42 Retinoids profoundly affect morphogenetic gradients and can induce and inhibit gene expression,18,35,38.45,48.49 Retinoids in combination with BMP 4 synergistically induce apoptosis}O It is clear, for example, that the retinoids have different effects on primitive mesenchymal tissue and on differentiated chondroosseous tissue.13.38,45,49 It is possible that these developmental differences in susceptibility to retinoid exposure could underlie the observed findings of isotretinoin therapy on patterns of orthotopic and heterotopic ossification in patients who have fibrodysplasia ossificans progressiva.
Despite the demonstration of some potential benefits of isotretinoin, there were several major shortcomings of the study. First, there was no comparable internal control group. Such a control group was virtually impossible to assemble considering the rarity of the disease, and the unwillingness of patients to participate in a controlled randomized study. It is doubtful that a randomized study could ever be performed in this group of patients.3, 21 Second, there were several ways in which the data from this study were not exactly comparable with the data in the external control group.7,36 In this study, regional anatomic involvement was assessed ographic, and radionuclide bone scan evalua~"" tion. In the external control group, regional anatomic involvement was assessed from patient questionnaires and clinical data alone. These differences in the methods of assessment resulted in a different definition of an involved anatomic region. This had two effects. First, because the definition was more sensitive in this study, the were biased against the effectiveness isotretinoin. Thus, a significant difference would have been harder to achieve, but should have been believable if it had occurred. Second, a patient would tend to have fewer anatomic regions at risk for future involvement under the criteria used in this study than under the criteria used in the external control survey; however, this produced no known bias in favor of isotretinoin effectiveness. Despite these limitations, the control population represented the most valid exter- tretinoin between I and 2 mg/kg per day was sufficient to achieve the observable effects while also minimizing the risk of unpleasant side effects. Fourth, patients in this study were treated for variable lengths of time. Some were unable to tolerate the side effects of the high dose medication, and stopped the medication early in the course of the protocol. Others who experienced major disease flareups while taking the isotretinoin, became discouraged and stopped the medication. Still others tolerated the isotretinoin, and elected to continue the medication indefinitely. Thus, the study may have inadvertently self selected for patients who responded more favorably to isotretinoin.
If isotretinoin therapy is considered, the authors recommend that the total daily steady state dose not exceed 2 mg/kg per day. Patients must be apprised fully of the potential side effects of treatment. Clinical symptoms, plasma triglyceride, and transaminase levels should be monitored.
To date, no modality (including isotretinoin) used in the prevention or treatment of fibrodysplasia ossificans progiessiva has proven to be fully effective in changing the inexorable natural history of the condition.2 Any enthusiasm that may exist for the use of isotretinoin in the treatment of patients who have fibrodysplasia ossificans progressiva must be tempered even further by the stark realization that the study was flawed by an imperfect control group, and that under the best of circumstances isotretinoin is not a panacea. Nevertheless, the limited benefits derived from isotretinoin therapy have revealed an option for treating some patients who have fibrodysplasia ossificans progressiva. The authors think that the search for a molecular cause for fibrodysplasia ossificans progressiva will le:lo to much more fruitful therapies.8. Bailar et al,3 have provided a detailed guideline for interpreting the value of studies without internal controls: "Sometimes questions of clinical interest can be addressed only by investigations without internal controls. Such studies nearly always make use of other types of comparisons (external controls) such as historical controls. These studies have a small but important and unique role in clinical investigation." Bailar and colleagues described five seminal features that added to the strength and clinical value of such studies: "I. An intent by the investigator expressed before the study that the treatment will affect the outcomes reported. 2. Planning of the analysis before the data are generated. 3. Articulation of a plausible hypothesis before the results are observed. 4. A likelihood that the results would have been of interest even if they had been opposite. 5. Reasonable grounds for generalizing the results from the study subjects to a broader group of patients. In spite of potential pitfalls, carefully selected and reported stud:' ies without internal controls can playa substantial part in the acquisition of scientific knowledge."3 Each of the five criteria for a valid external control group described by Bailar et al were met by this study.
Third, there were major differences in the steady state medication dosages throughout the study because many patients could not tolerate the unpleasant side effects of chronic high dose (5-8 mg/kg per day) isotretinoin therapy. Therefore, the dose of medication was reduced to the highest level tolerable in each patient. Despite the wide range of steady state medication dosages, there seemed to be no important difference in the inhibition of new heterotopic lesions in pre-\ luusly uninvolved regions between patients who received less than the median dose of 1.7 mg per day, and those who received more than that amount of medication. The data therefore suggested that a dose of iso-/, the .;tiveness 
